Chlorobutyl rubber (CIIR) - the halogenated butyl elastomer with chlorine substitution

Chlorobutyl rubber (CIIR - chlorinated isobutylene-isoprene rubber) is one of two halogenated butyl rubbers used in pharmaceutical vial stopper manufacture. The other is bromobutyl rubber (BIIR). Both start from the same base polymer - isobutylene-isoprene copolymer (IIR, butyl rubber) - and undergo a halogenation reaction that introduces reactive halogen atoms into the polymer chain. In CIIR, the halogen introduced is chlorine (Cl); in BIIR, it is bromine (Br). This single substitution difference between CIIR and BIIR has meaningful practical consequences for their extractables profiles, cure chemistry, and specific application suitability in pharmaceutical packaging.

The isobutylene-isoprene backbone - shared properties

Because CIIR and BIIR both derive from the same IIR backbone polymer, they share the fundamental performance properties of butyl rubber that make it the pharmaceutical industry's preferred stopper elastomer: extremely low gas permeability (the lowest of any commercial elastomeric material - important for maintaining headspace integrity and protecting oxygen-sensitive formulations), excellent chemical resistance to a wide range of aqueous formulations, and reliable self-sealing performance after needle puncture (elastomeric recovery that reseals the puncture channel after needle withdrawal).

The butyl backbone also provides a well-characterised baseline extractables profile compared to other elastomers - the compounding chemistry (vulcanisation agents, antioxidants, fillers, and processing aids) is well-understood and the extractables literature is extensive. Both CIIR and BIIR share this advantageous baseline.

The halogenation step - where CIIR and BIIR diverge

The halogenation reaction that converts IIR into CIIR or BIIR introduces reactive halogen atoms at specific positions on the isoprene units of the polymer chain. These halogen substituents participate in the vulcanisation (curing) reaction - they are the reactive sites that cross-link the polymer chains during the manufacturing of the rubber compound. The identity of the halogen (chlorine vs bromine) affects the reactivity of these cure sites, the kinetics of vulcanisation, and - critically for pharmaceutical applications - the nature of the halogen-derived species that can potentially be extracted from the cured stopper by the pharmaceutical formulation during fill-hold and shelf life storage.

CIIR produces chlorine-derived extractable species (chlorinated organics). BIIR produces bromine-derived extractable species (brominated organics). Whether this difference matters for a specific formulation depends on the formulation's sensitivity to these species - which is the central question the chlorobutyl vs bromobutyl stopper selection decision must answer.

Extractables-and-leachables programme outcome

The most scientifically grounded context for CIIR specification is an E&L programme finding where bromine-derived extractables from a BIIR stopper appear at concentrations that require documentation, qualification, or mitigation. Under ICH Q3D, USP <1664>, and the BioPhorum Operations Group extractables framework, individual leachable species must be characterised and assessed against their AET and relevant toxicological thresholds. Where a brominated extractable from BIIR exceeds its AET and cannot be mitigated adequately by stopper washing, coating, or formulation adjustment alone, switching to CIIR removes the entire class of bromine-derived extractables - replacing it with chlorine-derived species that are separately assessed and may have a different, more acceptable toxicological or AET status for the specific formulation and indication.

Biologic injectables with stringent E&L requirements

Small-molecule APIs where Br-derived AET is exceeded

Formulations requiring regulatory E&L submission package

Re-formulation projects switching from BIIR to CIIR

Acid-sensitive and pH-critical injectable formulations

Injectable formulations containing acid-labile APIs, or formulations where tight pH stability over the shelf life is a critical quality attribute, may benefit from compatibility testing with CIIR stoppers where compatibility studies with BIIR show pH drift or API degradation attributable to acidic extractable species with a bromine origin. This is a less common but documented rationale for CIIR specification, particularly in the development of injectable prodrug formulations and certain peptide injectables where acid-catalysed hydrolysis of the API is a principal degradation pathway. The choice must always be confirmed by formulation-specific compatibility data - the general principle cannot be applied without testing.

Acid-labile prodrug injectable formulations

pH-critical peptide and protein injectables

Ester-prodrug formulations sensitive to acid hydrolysis

Formulations where BIIR caused pH shift in stability study

regional regulatory expectations and established practices

In certain pharmaceutical markets and regulatory jurisdictions, CIIR has historically been more widely used than BIIR - either because of regional manufacturing traditions, historical supply chain choices, or regional pharmacopoeial conventions. A company entering a new market (particularly certain Asian and European markets) may find that existing reference products or local generic equivalents have used CIIR stoppers, creating a regulatory expectation of CIIR in the container-closure system description for that product category. In this context, CIIR specification is driven not by formulation chemistry but by the need to align the packaging specification with established regional practice or with a reference medicinal product's packaging system to support a regulatory comparability argument.

Products entering markets with established CIIR conventions

Generic products referencing a CIIR-stoppered innovator

Regulatory comparability to reference medicinal product

Established regional manufacturing practice alignment